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Abstract Chromatin remodeling and gene expression are
regulated by histone deacetylases (HDACs) that condense
the chromatin structure by deacetylating histones. HDACs
comprise a group of enzymes that are responsible for the
regulation of both cellular and viral genes at the transcrip-
tional level. In mammals, a total of 18 HDACs have been
identified and grouped into four classes, i.e., class I
(HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10),
class III (Sirt1–Sirt7), and class IV (HDAC11). We review
here the role of HDACs on viral replication and how
HDAC inhibitors could potentially be used as new
therapeutic tools in several viral infections.
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Introduction
Chromatin is the complex combination of DNA and
proteins that makes up chromosomes. It is divided between
heterochromatin (condensed) and euchromatin (extended)
forms. The major components of chromatin are DNA and
histone proteins, although many other chromosomal pro-
teins have prominent roles, too. The functions of chromatin
are to package DNA into a smaller volume to fit in the cell,
to strengthen the DNA to allow mitosis and meiosis, and to
serve as a mechanism to control expression and DNA
replication. Changes in chromatin structure are affected by
chemical modifications of histone proteins and by non-
histone DNA-binding proteins. The non-histone proteins
that are found associated with isolated chromatin fall into
several functional categories such as chromatin-bound
enzymes, high mobility group proteins (HMG), transcrip-
tion factors, and scaffold proteins. Thus, acetylation of
histone and non-histone chromosomal proteins by histone
acetyl transferases (HATs) leads to decondensation of the
chromatin. Chromatin remodeling and gene expression is
simultaneously regulated by histone deacetylases (HDACs)
that condense the chromatin structure by deacetylating
histones. HDACs comprise a group of enzymes that are
responsible for the removal of acetyl groups from a e-N-
acetyl lysine amino acids. As the organization and
packaging of eukaryotic DNA is achieved through the
addition of core histones H2A, H2B, H3, and H4, which
form the chromatin, the modification of core histones is of
fundamental importance to conformational changes in
chromatin.
The level of acetylation influences transcription activity.
The acetylation of histones results in the formation of
shapes of DNA that will serve as specific recruitment
platforms for other protein and enzyme complexes. These
multiprotein complexes will result in enhanced transcrip-
tional activity (euchromatin). By contrast, HDACs present
in a repressor complex deacetylate histone proteins, leading
to the recruitment of histone methyltransferase and result-
ing in subsequent methylation of histones. Ultimately,
proteins such as heterochromatin protein 1 (HP1) are
recruited to the repressor complex, leading to the formation
of condensed heterochromatin. Thus, HDAC activities are a
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HDAC family members
In mammals, a total of 18 HDACs have been identified and
grouped into four classes, i.e., class I (HDACs 1, 2, 3, 8),
class II (HDACs 4, 5, 6, 7, 9, 10), class III (Sirt1–Sirt7), and
class IV (HDAC11) (Table 1). The members of class I
HDACs contain a deacetylase domain and are the homo-
logs of yeast RPD3. They exhibit 45% to 93% amino acid
sequence identity and localize in the nucleus, except for
HDAC3. Class II HDACs are homologs of yeast Hda1 and
are present in both the nucleus and the cytoplasm (Martin et
al. 2009; Martin et al. 2007). HDAC6 is an exception which
contains two deacetylase domains, at both the N- and C-
terminus. The molecular weights of class II are twofold
higher than class I HDACs. The members of class III,
sirtuins, are homologs of yeast Sir2 and form a structurally
distinct class of NAD-dependent enzymes found in both the
nucleus and cytoplasm. HDAC11 has properties of both
class I and class II HDACs and represent class IV.
HDACs work in multi-subunit transcriptional co-
repressor complexes that are recruited by sequence-specific
transcription factors to promoter regions. There are several
co-repressor complexes for distinct promoters, which recruit
specific HDAC isoforms for silencing of target genes (Miska
etal.1999; Rayman et al. 2002). For example, HDACs 1, 2,
and 3 are majorly responsible for catalytic core for different
co-repressor complexes to achieve efficient transcriptional
repression. HDAC1 and HDAC2 are present in the
CoREST, Mi2/NuRD, and Sin3 complexes, whereas
HDAC3 is responsible for the catalytic activity of the N-
CoR and SMRT co-repressor complexes (Cress and Seto
2000; Mahlknecht et al. 2004; Ng and Bird 2000). HDACs
cooperate with various other transcriptional regulators such
as HDAC1 and HDAC2 associate with DNA methyltrans-
ferases (Burgers et al. 2002; Fuks et al. 2001) and histone
methyltransferases (HMTs) (Czermin et al. 2001). Further-
more, HDAC1 interacts with topoisomerase II enzyme that
is responsible for chromosome condensation (Tsai et al.
2000). However, little is known about the specificity of a
particular histone deacetylase enzyme for a specific lysine
residue. The preferential acetylation of H3K18 and H3K9
following knockdown of HDAC1 and HDAC3, respectively,
has been reported (Zhang et al. 2004). Non-histone
deacetylation-based gene expression involves the deacety-
lation of various transcription factors by HDACs. Deacety-
lation of sequence-specific transcription factors can
Histone
classes
Members Localization Target proteins (partial list)
Class I HDAC1 Nucleus AR, p53, E2F-1, SHP, STAT3, MyoD
HDAC2 Nucleus STAT3, Bcl6, glucocorticoid receptor GATA-1, STAT-3,
SHP, RelA, YY-1 HDAC3 Nucleus/
cytoplasm
HDAC8 Nucleus –
Class II HDAC4 Nucleus/
cytoplasm
GCMa, GATA-1, HP-1
HDAC5 Nucleus/
cytoplasm
GCMa, Smad7, HP-1
HDAC6 Mostly
cytoplasm
HSP70, Smad7, SHP, α-tubulin
HDAC7 Nucleus/
cytoplasm
PLAG1, PLAG2
HDAC9 Nucleus/
cytoplasm
–
HDAC10 Mostly
cytoplasm
–
Class III SIRT1 Nucleus NF-κB, p53, FOXO
SIRT2 Cytoplasm α-tubulin, H4
SIRT3 Nucleus/
mitochondria
Acetyl–CoA synthetases
SIRT4 Mitochondria Glutamate dehydrogenate
SIRT5 Mitochondria –
SIRT6 Nucleus DNA polymerase B
SIRT7 Nucleus RNA polymerase 1
Class IV HDAC11 Nucleus/
cytoplasm
–
Table 1 HDAC classification
depending on sequence identity
and domain organization
14 Clin Epigenet (2010) 1:13–24decrease their DNA binding activity and subsequently may
repress transcription. The covalent modifications of several
transcriptional factors, including E2F, sp3, p53, GATA1,
and TFIIF, have been reported (Ammanamanchi et al. 2003;
Boyes et al. 1998; Braun et al. 2001; Gu and Roeder 1997;
Imhof et al. 1997; Marzio et al. 2000). The specificity of
HDAC1 for p53 deacetylation, resulting in the degradation
of deacetylated p53 has been reported (Ito et al. 2002).
HDAC2 deacetylates the glucocorticoid receptor and
HDAC3 is needed for the deacetylation of myocyte
enhancer factor-2 (MEF-2) (Gregoire et al. 2007; Ito et al.
2006). HDACs are also involved in the deacetylation of
non-nuclear proteins like tubulin45 and HSP90 (Hubbert et
al. 2002; Kovacs et al. 2005).
HDAC in viral diseases
HDACs are involved in the regulation of the replication of
numerous viruses (Table 2). We will described here the role
of HDACs in viral diseases including hepatitis B and C,
HIVand HPV infections, and infections with Herpesviridae
(HSV, HCMV, EBV) and Paramyxoviridae (RSV).
The hepatitis B virus x (HBx) protein plays a critical role
in liver carcinogenesis. HBx has been reported to activate
cyclin D1. HBx induces the expression of metastasis-
associated protein 1 (MTA1), a protein closely related to
tumorgrowthand metastasis invarious cancers, especially in
hepatocellular carcinoma (HCC). In addition, HBx has been
reported to modulate hypoxia-inducible factor-1 alpha (HIF-
1 alpha) expression and activity, and HIF-1 alpha increased
expression has been correlated with tumor growth and poor
patient prognosis (Semenza 2004). Under conditions of
normoxia, post-translational modifications including the
hydroxylation of proline residues and acetylation of a
lysine residue within the oxygen-dependent degradation
domain promote HIF-1α interaction with von Hipple–
Lindau (pVHL) ubiquitin E3 ligase complex. This occurs
concurrently with the hydroxylation of an asparagine
residue by the aparaginyl hydroxylase FIH-1 and inhibits
Table 2 Role of HDACs in viral infections
Virus HDAC Molecular mechanism Clinical effect References
DNA viruses
HBV HDAC1,
2
HBx forms a multiprotein complex
HDAC1/2, MTA1, HIF-1
Angiogenesis and metastasis of
HBV-associated HCC
Semenza 2004; Yoo et al. 2008
HCMV HDAC3 HDAC3 represses the HCMV MIEP Repression of viral replication Meier 2001; Murphy et al. 2002
HSV-1 HDAC1 HDAC represses viral transcription
during latency via HCF-1. ICP0
inhibits the HDAC1/CoREST complex
and favor the HSV reactivation
Control of HSV-1 latency and
reactivation in neurons
Wysocka et al. 2003, Everett et al. 2009
EBV HDAC1,
2, 7
Histone deacetylation in response to
phosphorylated MEF-2D transcription
factor. HDAC7 represses the Zp pro-
moter. HDAC1/2 represses the TRF2
promoter binding
Control of EBV latency Gruffat et al. 2002; Bryant and Farrell
2002; Zhou et al. 2009
HPV HDAC1 E7 viral oncoprotein disrupts the Rb/
E2F/HDAC1 repressor complexes and
favors cdc25A transcription. E7 binds
HDAC and favor E2F2 transcription in
keratinocytes. E7 recruits HDAC and
blocks the IRF-1 transactivation func-
tion, a tumor suppressor
E7 HPV favors carcinogenesis
through binding to cellular
factors involved in cell cycle
regulation and differentiation
Nguyen et al. 2002; Longworth &
Laimins 2004; Park et al. 2000
RNA viruses
HCV HDAC HDAC favors the expression of HIF, a
hepcidin regulator
HCV-induced oxidative stress
suppresses hepcidin expression
Miura et al. 2008
HIV HDAC
class I
& class
II &
class III
HDAC represses the HIV-1 LTR tran-
scription through the formation of
inhibitory complexes including
HDACs and several transcription fac-
tors and repressor proteins. HIV-1
virion-associated HDAC1 could favor
early post-entry events. SIRT1 regu-
lates HIV transcription via Tat
deacetylation
Formation of HIV cellular
reservoirs in both myeloid and
lymphoid cells resulting in
viral persistence
Van Lint et al. 1996, Coull et al. 2000,
Williams et al. 2006, Marban et al.
2005, Marban et al. 2007, Rohr et al.
2003; Reuse et al. 2009; Imai &
Okamoto 2006; Jiang et al. 2007;
Sorin et al. 2009; Pagans et al. 2005;
Kwon et al. 2008; Zhang et al. 2009
RSV HDAC1 HDAC1 associates with STAT1 and Bcl-
3 on the IL-8 promoter
Decreased IL-8 production dur-
ing airway inflammation to
favor RSV replication
Jamaluddin et al. 2005
Clin Epigenet (2010) 1:13–24 15the binding of transcriptional co-activators p300 and CBP
to HIF-1α. These events result in polyubiquitination and
the proteosomal degradation of HIF-1α. In contrast,
conditions of cellular hypoxia result in HIF-1α-stabilized
expression by remaining unhydroxylated and deacetylated,
especially via class II HDAC activation (Qian et al. 2006).
Stabilized HIF-1α escapes pVHL-mediated degradation
and is able to bind p300 and CBP where it translocates to
the nucleus from the cytoplasm and heterodimerizes with
HIF-1β to initiate the transcription of its target genes.
During HBV infection, especially at the stage of HCC,
hypoxia occurs, resulting in HIF-1alpha overexpression
parallel to HBx upregulation. In the presence of HBx,
HDAC1/2 and MTA1 physically associate with HIF-1
alpha in vivo. Thus, a positive cross-talk between HBx
and the MTA1/HDAc complex in stabilizing HIF-1 alpha
may play a critical role in angiogenesis and metastasis of
HBV-associated HCC (Yoo et al. 2008).
HCV-induced oxidative stress suppresses the expression
of hepcidin, a negative regulator of iron absorption. Hypoxia
and chemical stabilizers of the HIF-1 alpha have also been
shown to suppress hepcidin expression (Volke et al. 2009).
Expression of hepcidin inhibitor, HIF, is increased by
HDAC, suggesting that HCV-induced oxidative stress
suppresses hepcidin expression through increased HDAC
activity resulting in increased HIF-1 alpha activity (Miura
et al. 2008).
After entry into the target cell and reverse transcrip-
tion, HIV-1 genes are integrated into the host genome. It
is now well established that the viral promoter activity is
directly governed by its chromatin environment (Van Lint
2000). Epigenetic modifications and disruption of Nuc-1,
a nucleosome located immediately downstream of the
transcriptional initiation site that directly impedes LTR
activity, are a prerequisite to the activation of LTR-driven
transcription and viral expression (Van Lint 2000;V a n
Lint et al. 1996;V e r d i ne ta l .1993). The compaction of
chromatin and its permissiveness for transcription are
directly dependent on the post-translational modifications
of histones such as acetylation, methylation, phosphory-
lation, and ubiquitination (Fischle et al. 2003). In contrast
to productively infected cells, latently infected cells
frequently harbor HIV-1 genomes integrated in hetero-
chromatic structures, which allows the viral persistence of
silenced integrated proviruses (Jordan et al. 2003). These
observations might at least partially explain how the virus
can form viral reservoirs in some target cells and thereby
fuel the progression of the disease (Finzi et al. 1997;
Pierson et al. 2000). Some transcription factors, such as
YY1 and LSF, repress the transcription from the HIV-1
LTR by recruiting HDAC1 to the repressor complex
(Coull et al. 2000). In agreement with these data, HIV-1
gene transcription has been shown to be activated by
trichostatin A (TSA) treatment, and several transcription
factors bound to the viral LTR recruit class I or II HDAC
(Coull et al. 2000;V a nL i n te ta l .1996; Williams et al.1
2006). HP1 is a transcriptional repressor that directly
binds to the methylated lysine 9 residue of histone H3
(H3K9me), which is a hallmark histone modification for
transcriptionally silenced heterochromatin (Zeng et al.
2010; Bannister et al. 2001). The levels of trimethylated
histone H3 and HP1-alpha associated with HIV proviruses
have been reported to fall rapidly after TNF alpha
activation, indicating that epigenetic mechanisms targeting
chromatin structures selectively restrict HIV transcription
(Pearson et al. 2008).
COUP-TF interacting protein 2 (CTIP2) is a recently
cloned transcriptional repressor that can associate with
members of the COUP-TF family (Avram et al. 2000).
CTIP2 has been reported to inhibit HIV-1 replication in
human microglial cells (Marban et al. 2005; Marban et al.
2007; Rohr et al. 2003). Microglial cells constitute the
central nervous system resident macrophages and have
been described as latently HIV-1-infected cellular reservoirs
(Barber et al. 2006). However, contrary to CD4+ T
lymphocyte reservoirs (Marcello 2006), within macro-
phages and microglial cells CTIP2 inhibits HIV-1 gene
transcription (reviewed in Redel et al. 2010). CTIP2 recruits
HDAC1 and HDAC2 to promote local histone H3
deacetylation at the HIV-1 promoter region and also
associates with the histone methyltransferase SUV39H1,
which increases local histone H3 lysine 9 methylation.
Thereafter, HP1 proteins are recruited to the viral promoter,
leading to the formation of local heterochromatin and
subsequently to HIV-1 silencing (Marban et al. 2007).
p21WAF1 is a major cell cycle regulator of the response
to DNA damage, senescence, and tumor suppression and its
induction upon HIV-1 infection favors HIV-1 replication in
macrophages. CTIP2 is recruited to the p21 gene promoter,
resulting in the silencing of p21 gene transcription through
interactions with histone deacetylases and methyltrans-
ferases SUV39H1, and therefore could abolish Vpr-
mediated stimulation of p21, thereby indirectly contributing
to HIV-1 latency (Cherrier et al. 2009). Besides CTIP2, the
AP-4 site within the HIV-1 LTR represses HIV-1 gene
expression by recruiting HDAC1 (Imai and Okamoto
2006). Also, c-Myc and Sp1 transcription factors contribute
to proviral latency by recruiting HDAC1 to the HIV-1 LTR
(Jiang et al. 2007).
HIV-1 integrase and INI1/hSNF5, a component of the
SWI/SNF complex, bind SAP18 (Sin3a-associated protein,
18 kDa), a component of the Sin3a-HDAC1 complex, and
selectively recruit components of Sin3a–HDAC1 complex
into HIV-1 virions (Sorin et al. 2009). Thus, HIV-1 virion-
associated HDAC1 is required for efficient early post-entry
events.
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cdk9/cyclin T1 complexes, resulting in Tat acetylation by
the transcriptional coactivator p300, thereby facilitating
transcription initiation. Acetylated Tat dissociates from the
TAR RNA structure and recruits bromodomain-binding
chromatin-modifying complexes such as p/CAF and SWI/
SNF to facilitate transcription elongation (Agbottah et al.
2006). By contrast, Tat is deacetylated by human sirtuin 1
(SIRT1), a nicotinamide adenine dinucleotide-dependent
class III protein deacetylase in vitro and in vivo (Pagans et
al. 2005; Zhang et al. 2009), supporting a model in which
cycles of Tat acetylation and deacetylation regulate HIV-1
transcription (Blazek and Peterlin 2008; Kwon et al. 2008).
Upon infection of permissive cells such as fibroblasts,
epithelial cells, endothelial cells, and macrophages, human
cytomegalovirus (HCMV) undergoes an ordered cascade of
gene expression. The major immediate early (IE) genes are
the first transcribed, resulting in two abundant proteins, IE1
p72 and IE2 p86 (Stenberg et al. 1989), which are able to
autoregulate the major immediate early promoter (MIEP)
(Cherrington and Mocarski 1989; Pizzorno et al. 1988). It is
known that expression from the MIEP is at least partly
determined by cellular factors such as NF-kB/rel, CREB/
ATF, SP-1, AP-1, Bcl-3, serum response factor, and ELK-1,
which all promote activity by binding one or more sites in
the enhancer (Chan et al. 1996; Kowalik et al. 1993; Lang
et al. 1992; Liu and Stinski 1992; Sambucetti et al. 1989;
Wade et al. 1992; Khan et al. 2009). In contrast, the MIEP
is also regulated by cellular repressors, such as MBFs,
YY1, MRF and Gfi-1, which bind to the MIEP and all are
preferentially expressed in undifferentiated cells (Huang et
al. 1996; Liu et al. 1994; Shelbourn et al. 1989; Zweidler-
Mckay et al. 1996). The chromatin structure around the
MIEP changes with cellular differentiation and thus may
play a role in controlling HCMV latency and reactivation.
T2 cells are normally non-permissive for HCMV infection;
however, following treatment with TSA, T2 cells can be
rendered transiently permissive for HCMV (Meier 2001),
suggesting that HDACs play a role in the repression of viral
replication. HDACs have been reported as limiting HCMV
infection as the relatively high levels of HDAC3 in T2 cells
and monocytes correlate with non-permissiveness for
HCMV (Murphy et al. 2002). Furthermore, fibroblasts,
which are fully permissive for HCMV, contain little
HDAC3, implying that the relative level of HDAC may
be important for HCMV permissiveness in a range of cell
types. HDAC3 acts as a repressor of the HCMV MIEP
since superexpression of HDAC3 appeared most effective
at inhibiting viral infection in permissive T2RA cells
(Murphy et al. 2002).
Changes in chromatin structure have been implicated in
the control of latency in herpesviruses. Latent herpes
simplex virus type 1 (HSV-1) DNA is associated with
nucleosomes in vivo (Deshmane and Fraser 1989). Follow-
ing TSA treatment of neurons latently infected with a
recombinant HSV-1, the activity of the viral immediate
early promoter increased significantly (Arthur et al. 2001),
suggesting that HDACs may play a role in controlling
HSV-1 latency. The abundant and chromatin-associated
protein HCF-1 is a critical player in HSV transcription.
HCF-1 associates with the Sin3 HDAC and human
trithorax-related Set1/Ash2 histone methyltransferase
(Wysocka et al. 2003). HCF-1 tethers the Sin3 and Set1/
Ash2 transcriptional regulatory complexes together even
though they are generally associated with opposite
transcriptional outcomes: repression and activation of
transcription, respectively. Nevertheless, this tethering is
context-dependent because the transcriptional activator
VP16 selectively binds HCF-1 associated with the Set1/
Ash2 HMT complex in the absence of the Sin3 HDAC
complex (Wysocka et al. 2003). These results suggest that
HCF-1 can broadly regulate transcription, both positively
and negatively, through selective modulation of chromatin
structure. HSV-1 immediate early regulatory protein ICP0
is important for stimulating the initiation of the lytic cycle
and efficient reactivation of latent or quiescent infection.
ICP0 inhibits cellular HDAC activity through an interac-
tion with the HDAC-1 binding partner CoREST (Everett
et al. 2009).
Like HSV-1, in latent Epstein–Barr virus (EBV), DNA is
organized in nucleosomes (Dyson and Farrell 1985; Jenkins
et al. 2000; Shaw et al. 1979) and the switch to productive
EBV infection is believed to involve the activation of the IE
gene BZLF1 (Countryman and Miller 1985). Although it
was proposed that HDACs 4 and 5 are the HDACs which
might mediate the repression of Zp (Gruffat et al. 2002),
direct measurement of the expression of class II HDACs
has shown that HDACs 4 and 5 are undetectable but
HDAC7 is the most readily detected class II HDAC in Raji
cells, suggesting that it may be involved in the repression of
the Zp promoter of the EBV BZLF1 gene during latency
(Bryant and Farrell 2002). Moreover, the promoter of
BZLF1 is more associated with acetylated histones follow-
ing activation of EBV-positive AK6 cells (Jenkins et al.
2000). During EBV latency, latent membrane protein
(LMP)-1 expression induces several B lymphocyte activa-
tion markers, including intercellular adhesion molecule
(ICAM)-1. HDAC inhibition induces the latent form of
LMP-1 expression in EBV-positive cell lines, resulting in
ICAM-1 expression upregulation and homotypic adhesion
(Park and Faller 2002). The primary events in EBV
reactivation involve dephosphorylation of the MEF-2D
transcription factor. Dephosphorylation of MEF-2D is
known to be associated with histone acetylase recruitment
(Bryant and Farrell 2002). Histone deacetylation in
response to phosphorylated MEF-2D can be mediated by
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repeat factor 2 (TRF2) binding at the EBVorigin of plasmid
replication (OriP) represses EBV replication. HDAC1 and
HDAC2 form a stable complex with TRF2 at OriP and
enhance EBV episome stability by providing a checkpoint
that delays replication initiation at OriP (Zhou et al. 2009).
Respiratory syncytial virus (RSV) is a paramyxovirus
that produces airway inflammation, in part by inducing
interleukin-8 (IL-8) expression, a CXC-type chemokine, via
the NF-kB/RelA and STAT/IRF signaling pathways. In
RSV-infected A549 cells, IL-8 transcription attenuates after
24 h in spite of ongoing viral replication and persistence of
nuclear RelA, suggesting a mechanism for transcriptional
attenuation (Jamaluddin et al. 2005). RSV infection induces
Bcl-3 expression 6 to 12 h after viral infection, at times
when IL-8 transcription is inhibited. Nuclear Bcl-3 asso-
ciates with STAT1 and HDAC1, increasing HDAC1
recruitment to the IL-8 promoter. Treatment with TSA
blocks the attenuation of IL-8 transcription (Jamaluddin
et al. 2005). Thus, Bcl-3 is a RSV-inducible inhibitor of
IL-8 transcription by interfering with the NF-kB and STAT/
IRF signaling pathways by complexing with them and
recruiting HDAC1 to attenuate target promoter activity.
The activities encoded by the early gene product E7 are
essential to the oncogenic properties of human papilloma-
virus type 16 (HPV-16) (Longworth et al. 2005). HPV-16
E7 binds to cellular factors involved in cell cycle regulation
and differentiation. The cdc25A tyrosine phosphatase is
required for G(1)/S transition, and its deregulation is
associated with carcinogenesis. HPV-16 E7 can directly
target cdc25A transcription and maintains cdc25A gene
expression by disrupting Rb/E2F/HDAC1 repressor com-
plexes (Nguyen et al. 2002). The interaction of E7 with
HDACs is essential for extending the life span of
keratinocytes and for stable maintenance of viral genomes
(Longworth and Laimins 2004). E7 activates the E2F2
transcription in suprabasal keratinocytes through its ability
to bind HDACs (Longworth et al. 2005). Other studies have
found that growth arrest of HPV-positive cells after HDAC
inhibition is independent of E6/E7 oncogene expression
(Finzer et al. 2002). HPV E7 protein is functionally
associated with the interferon regulatory factor (IRF)-1
tumor suppressor in cervical carcinogenesis. Under TSA
treatment, the repressing activity of E7 is released in a
dose-dependent manner (Park et al. 2000), suggesting that
HPV E7 interferes with the transactivation function of
I R F - 1b yr e c r u i t i n gH D A Ct ot h ep r o m o t e r .
HDACs: new therapeutic targets in viral diseases?
There are several HDAC inhibitors. The “classical” HDAC
inhibitors act exclusively on class I and class II HDACs by
binding to the zinc-containing catalytic domain of the
HDACs. These classical HDAC inhibitors fall into several
groupings:
1. hydroxamic acids, such as trichostatin A
2. cyclic tetrapeptides (such as trapoxin B) and the
depsipeptides
3. benzamides
4. electrophilic ketones
5. the aliphatic acid compounds such as phenylbutyrate
and valproic acid
The “second-generation” HDAC inhibitors include the
hydroxamic acids vorinostat (SAHA), belinostat (PXD101),
LAQ824, and panobinostat(LBH589) and the benzamides
entinostat (MS275), CI994, and mocetinostat
(MGCD0103). The sirtuin class III HDACs are NAD+
dependent and are therefore inhibited by nicotinamide, as
well derivatives of NAD, dihydrocoumarin, naphthopyr-
anone, and 2-hydroxynaphaldehydes.
HDAC inhibitors (HDACi) could potentially be used as
new therapeutic tools in several viral infections. First,
HDACi could reactivate the latent virus present in infected
cells and thereby favor the clearance of the virus from
cellular reservoirs such as in HIV and HCMV infections.
Second, HDACi could favor the apoptosis of infected cells
and also could thereby lead to the elimination of infected
cells. This mechanism could be used to kill transformed
cells infected by viruses such as HPV and EBV.
HDACi as therapeutic tools to reactivate latent virus
from cellular reservoirs
The ability of HIV to establish a latent infection causes life-
long virus persistence, even after long-term highly active
antiretroviral therapy (HAART). The role that latency is
playing in preventing the clearance of the virus infection has
become evident in recent years. Patients who have been
successfully treated with HAART, having undetectable
levels of viral RNA (below 40 copies/ml) in the plasma for
years, experience rapid virus rebound on withdrawal of
therapy. Activation of latent proviruses from the infected
cells in combination with HAART is a therapeutic strategy
that may lead to the complete elimination of HIV infection
(Colin and Van Lint 2009). Combination therapy with an
HDAC inhibitor such as TSA and intensified HAART has
been shown to safely accelerate the clearance of HIV from
resting CD4+ T cells in vivo, suggesting a new and
practical approach to eliminate HIV infection in this
persistent reservoir (Lehrman et al. 2005). By contrast,
more recent data indicate that the stability of the latent
reservoir despite intensive therapy requires new strategies
to eradicate HIV-1 from this reservoir (Gandhi et al. 2010;
Sagot-Lerolle et al. 2008; Archin et al. 2010).
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promoter of HIV-1 to maintain proviral latency. HDAC
inhibition leads to promoter expression and the escape of
HIV from latency. After exposure to pyrrole–imidazole
polyamides that specifically block HDAC1 recruitment
by the transcription factor LSF to the HIV promoter,
replication-competent HIV is recovered from the cultures
of resting CD4+ T cells in HIV-infected patients whose
viremia had been suppressed by therapy (Ylisastigui et al.
2004a). Class I HDAC inhibitors such as suberoylanilide
hydroxamic acid (SAHA, Vorinostat) have been tested ex
vivo on HIV-1-infected cells isolated from the peripheral
blood of patients (Quivy et al. 2007). In the resting CD4+ T
cells of antiretroviral-treated aviremic HIV-infected
patients, clinically achievable exposures to SAHA induced
virus outgrowth ex vivo (Archin et al. 2009a; Edelstein et
al. 2009). Valproic acid (VPA) induces acetylation at the
integrated HIV proviral promoter, but CD4 cells exposed to
VPA do not become activated or more permissive for de
novo HIV infection. VPA induces outgrowth of HIV from
the resting CD4+ T cells of aviremic patients at concen-
trations achievable in vivo (Ylisastigui et al. 2004b). In
addition, combination therapy with oral VPA (500–750 mg,
twice daily) added to intensified HAART for 3 months
safely accelerates the clearance of HIV from resting CD4+
T cells in vivo, suggesting a way to eliminate HIV infection
in the persistent reservoir (Lehrman et al. 2005). Class I
HDACi are a strikingly efficient inducer of virus outgrowth
from resting CD4+ T cells of aviremic patients, whereas
HIV is rarely recovered from patient’s cells exposed to class
II HDACi (Archin et al. 2009b). Since global HDAC
inhibition can induce host cytotoxicity, the RNA expression
and protein expression and compartmentalization of
HDAC1 to HDAC11 in the resting CD4+ T cells of HIV-1-
positive aviremic patients were recently assessed. Although
all HDACs were detected in resting CD4+ T cells, targeted
inhibition of HDACs by small-interfering RNA demonstrat-
ed that mostly HDAC2 and HDAC3 contribute to the
repression of HIV-1 LTR expression (Keedy et al. 2009).
Therefore, HDACi specific for a limited number of class I
HDACs may offer a targeted approach to the disruption of
persistent HIV-1 infection. Thus, potent selective HDACi
may allow improved targeting of persistent proviral
infection in HIV-infected patients.
Recently, a strong synergistic activation of HIV-1 pro-
duction by clinically used histone deacetylase inhibitors
(HDACis) combined with prostratin, a non-tumor-
promoting nuclear factor (NF)- κB inducer, was shown
using the latently infected U1 monocytic cell line and
latently infected J-Lat T cell clones (Reuse et al. 2009).
Mechanistically, HDACis increased prostratin-induced
DNA-binding activity of nuclear NF-κB and degradation
of cytoplasmic NF-κB inhibitor, IκBα. Moreover, the
combined treatment prostratin+HDACi caused a more
pronounced nucleosomal remodeling in the U1 viral
promoter region than the treatments with the compounds
alone. This more pronounced remodeling correlated with a
synergistic reactivation of HIV-1 transcription following the
combined treatment prostratin+HDACi. The physiological
relevance of the prostratin+HDACi synergism has been
shown in CD8
+-depleted peripheral blood mononuclear
cells from HAART-treated patients with undetectable viral
load (Reuse et al. 2009). Moreover, this combined
treatment reactivated viral replication in resting CD4
+ T
cells isolated from similar patients. Viral reactivation assays
have shown in cell cultures prepared from HAART-treated
HIV-1-infected individuals with undetectable viral load that
a combination prostratin+VPA or prostratin+SAHA can
induce HIV-1 recovery in CD8
+-depleted PBMC cultures
tested. Moreover, the combination prostratin+SAHA can
reactivate viral replication in HLA DR
− CD4
+ T cell
cultures prepared from additional patients (Reuse et al
2009). Altogether, these results suggest that combinations
of different kinds of proviral activators may have important
implications for reducing the size of latent HIV-1 reservoirs
in HAART-treated patients, not only in CD4+ T cells but
also in monocytes/macrophages. Interestingly, resveratrol, a
SIRT1 activator, has been recently reported to inhibit in
vitro Tat-induced HIV-1 LTR transactivation via NAD(+)-
dependent SIRT1 activity (Zhang et al. 2009). Besides
HDACi, resveratrol and related compounds may represent
as potential candidates for novel anti-HIV therapeutics.
Beside HIV, other viruses could potentially be targeted
by HDACi to clear cellular reservoirs of virions. HCMV
has been reported to replicate at low levels in infected cells
and to be reactivated upon immune suppression, especially
in transplant recipients (Coaquette et al. 2004). Recently,
we reported that the activation of p52/Bcl-3 NF-kB
complexes in primary macrophages and p50/p65 NF-kB
complexes in fibroblasts in response to HCMV infection
could explain the low-level growth of the virus in macro-
phages versus efficient growth in fibroblasts (Khan et al.
2009). The low level sustained replication of HCMV in
macrophages could favor the formation of reservoirs of
virions, and the use of HDACi could reactivate the virus
which could be targeted with antiviral compounds such as
ganciclovir. Thus, the use of HDACi in addition to antiviral
treatment could be a new promising approach in several
viral infections including HIV-1, but also herpesviruses
such as HCMV and others.
HDACi as therapeutic tools to kill virus-induced
transformed cells
Cervical cancer cells are addicted to the expression of the
HPV oncoproteins E6 and E7. The oncogenicity of E6 is
Clin Epigenet (2010) 1:13–24 19mediated in part by targeting p53 and PDZ-family tumor
suppressor proteins for rapid proteosomal degradation,
whereas the E7 oncoprotein acts in part by coopting
HDAC1/2. Immunohistochemical analysis reveals elevated
HDAC1/HDAC2 expression in cervical dysplasia and
cervical carcinoma versus normal cervical epithelium.
HDACi sodium butyrate and TSA arrest HPV-positive
carcinoma cells in G1 to S transition of the cell cycle, which
is paralleled by an upregulation of the cyclin-dependent
kinase inhibitors (CKIs) p21CIP1 and p27KIP1 as well as
the complete loss of cdk2 activity. HDAC inhibition
triggered an E7-dependent degradation of pRb, while the
levels of E2F remained unaffected. The presence of free
intracellular E2F and the concomitant upregulation of CKIs
duringG1arrestrender thecellstoundergoapoptosis(Finzer
et al. 2001). In addition, HDACi induce an intrinsic type of
apoptosis in HPV-positive cells by disrupting the mito-
chondrial transmembrane potential (Finzer et al. 2004). The
HPV oncogenic proteins E6 and E7 are able to inactivate
p53 and pRb proteins, which results in malignant transfor-
mation. Apicidin HDACi significantly reduces HPV16-E6
and -E7 protein levels in cervical cancer cells (Luczak and
Jagodzinski 2008).
The combination of bortezomib, a proteosome inhibitor,
and HDACi TSA or SAHA shows the synergistic killing of
HPV-positive, but not HPV-negative, cervical cancer cell
lines (Lin et al. 2009). Thus, a combination of HDAC and
proteosome inhibitors, including SAHA and bortezomib,
respectively, warrants exploration for the treatment of
cervical cancer.
Latent infection of the EBV is strongly associated with
the pathogenesis of several tumor types. The restricted
expression of the latent EBV antigens is critical for EBV-
associated tumors to escape from immune surveillance.
TSA causes cell cycle arrest at low concentrations and
induces apoptosis at higher (>300 nM) concentrations in
the EBV-transformed lymphoblastoid cell lines (LCLs)
(Seo et al. 2008). Following TSA treatment, a reduced
expression of cyclin D2 and an induction of p21 may play
an essential role for G1 arrest in LCLs. In addition, TSA
induces EBV lytic replication cycle in LCL cells (Seo et al.
2008; Ye et al. 2007). Thus, TSA may exert an enhanced
anti-tumor effect for EBV-associated tumors not only by
inducing a cell cycle arrest and apoptosis but also by
triggering an EBV lytic cycle. Finally, combining the use of
a chemotherapeutic agent with oncolytic virotherapy is a
useful way to increase the efficiency of the treatment of
cancer. Replication-conditional (oncolytic) mutants of HSV
are considering promising therapeutic alternatives for
human malignancies. VPA pretreatment improves the
propagation and therapeutic efficacy of oncolytic HSV in
a human glioma xenograft model in vivo (Otsuki et al.
2008). TSA can be used as an enhancing agent for
oncolytic virotherapy for oral squamous cell carcinoma
with gamma(1)34.5 gene-deficient HSV-1 (Katsura et al.
2009). Altogether, HDACi can improve the efficacy of
tumor virotherapies.
Hepatitis B oncoprotein, HBx, estrogen receptor (ER)
alpha, and HDAC1 form a ternary complex (Han et al.
2006). Tricostatin A restores the transcriptional activity of
ERalpha inhibited by HBx. Since estrogen, which exerts its
biological function through ER, can inhibit HBV replica-
tion, ERalpha agonists may be developed for HCC therapy.
Although the killing of infected cells via apoptosis using
HDACi has shown a “proof-of-concept” in oncology,
additional experiments have to be performed to determine
if this approach is translatable to patients without malig-
nancy and/or if it will succeed in the absence of a second
drug and/or an alternative treatment. Future studies will be
needed to further test this hypothesis.
Conclusion
HDACs are critical factors involved in the control of viral
replication. The molecular mechanisms underlying the role
of HDACs in viral latency, viral reactivation, and carcino-
genesis are progressively unveiled. The use of HDAC
inhibitors as therapeutic tools to reactivate latent virus from
cellular reservoirs may have important implications for
reducing the size of latent viral reservoirs in patients infected
with HIV and herpesviruses (HCMV, HSV, EBV). In
addition, HDACi could be promising drugs which will kill
virus-induced transformed cells especially in HPV and EBV
infections. A better understanding of the role of HDACs in
viral diseases will lead to the development of new drugs,
especially HDAC inhibitors that will target cellular and viral
proteins actively involved in numerous viral diseases.
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